The ACOORH Study
Research type
Research Study
Full title
The ALMASED Concept against Overweight and Obesity and Related Health Risk (ACOORH)
IRAS ID
156108
Contact name
H. David McCarthy
Contact email
Sponsor organisation
Almased Wellness GmbH
Duration of Study in the UK
1 years, 6 months, 30 days
Research summary
Obesity continues to be a major public health and clinical problem. It is the main risk factor for type 2 diabetes and heart and blood vessel (cardiovascular) disease as well as a number of other chronic conditions including certain cancers. Weight loss is the most effective approach to reducing the risk of these diseases in overweight and obese individuals. Apart from invasive surgery, a long term low calorie/healthy diet coupled with increased physical activity remains the best approaches to weight loss.
A meal replacement product, which can substitute between 1 and 3 meals per day, is one approach to achieving a lower energy (calorie) intake to aid weight loss. Almased is one such meal replacement product. The aim of this study is to learn more about how effective Almased can be, compared with a control group of obese individuals given healthy eating and lifestyle advice, on mid to long term weight loss, as well as on a number of measures of risk for heart disease and diabetes. Almased is a low calorie drink composed of soy protein, skimmed milk yogurt and honey extract, supplemented with vitamins and minerals and will be consumed daily for 12 months by a group of overweight/obese participants. Intervention with this meal replacement product could prove to be a relatively simple, inexpensive and effective way of assisting the weight loss process.
Study participants will undergo regular clinical assessments, blood measurements and body composition measurements and questionnaires relating to physical activity levels and quality of life. This study will be conducted by London Metropolitan University in collaboration with the Clinical Research Centre at Barts and the London NHS Trust and will be replicated at a number of centres in Germany, France, Austria and Switzerland.
REC name
Wales REC 4
REC reference
15/WA/0118
Date of REC Opinion
30 Apr 2015
REC opinion
Further Information Favourable Opinion